<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313039</url>
  </required_header>
  <id_info>
    <org_study_id>20100252</org_study_id>
    <nct_id>NCT01313039</nct_id>
  </id_info>
  <brief_title>Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer</brief_title>
  <official_title>Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      If AZD6244 is able to increase ER expression in ER-negative/low cancers then it may be
      possible to effectively use hormonal therapy in these patients resulting in improved
      outcomes. The investigators propose a single-arm Simon two-step study to examine whether
      treatment with AZD6244 will result in increased ER expression in ER-negative/low primary
      breast tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase of ER Protein Expression in ER-Negative/Low Breast Cancer</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate in a clinical neoadjuvant model whether MEK inhibitor AZD6244 can increase ER protein expression in ER-negative/low breast cancer, as measured by the &quot;ER response rate&quot; by both standard immunohistochemistry and Allred Score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in ER-regulated Gene Expression in E-negative/Low Breast Cancer</measure>
    <time_frame>2 Years</time_frame>
    <description>To assess for changes in ER-regulated gene expression in ER-negative/low breast tumors following AZD6244 therapy through assessment of protein expression by immunhistochemistry in paraffin embedded tissues.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ER Promoter Methylation in ER-negative/Low Breast Cancer</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the rate of ER promoter methylation in ER-negative/low breast cancer tumors that do not attain an ER response following AZD6244 therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Vitro Tamoxifen Response in Tumors</measure>
    <time_frame>2 years</time_frame>
    <description>To assess for in vitro tamoxifen response in tumors following therapy with AZD6244.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AZD6244</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZ6244</intervention_name>
    <description>AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15</description>
    <arm_group_label>AZD6244</arm_group_label>
    <other_name>AZD6244</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female breast cancer patient &gt; 18 years.

          -  Patients must have biopsy-proven clinical Stage Ic-III invasive breast carcinoma with
             â‰¤ 10% ER expression by immunohistochemistry (IHC) analysis.

          -  Patients must have a pre-treatment baseline core biopsy or incisional biopsy available
             for additional testing (ER, protein/gene expression analysis).

          -  Patients must have sufficient tumor remaining following diagnostic biopsy that
             requires an additional definitive surgical procedure per the standard of care. Planned
             procedure may include lumpectomy or mastectomy as clinically indicated.

          -  Patients must have an ECOG Performance Status of 0 - 1.

          -  Patients must have the ability to understand and willingness to sign an English or a
             Spanish language written informed consent document.

        Exclusion Criteria:

          -  Male breast cancer patient.

          -  Patients who are pregnant or breast-feeding are excluded from the study due to
             potential harm to the fetus or nursing infant from the study therapy. Patients of
             reproductive potential must consent to use of contraception or abstinence to be
             eligible for the study.

          -  Patients may not have received prior chemotherapy or hormonal therapy for treatment of
             the current breast cancer.

          -  Patients should not have known or strongly suspected BRCA mutation by history (genetic
             testing not required).

          -  Patients will have pre-study testing, including history and physical exam, complete
             blood count, and measurement of renal and hepatic function. Patients will be
             ineligible for the study if significant abnormalities are detected, in accordance with
             good medical practice.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Hurley, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2011</study_first_submitted>
  <study_first_submitted_qc>March 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2011</study_first_posted>
  <results_first_submitted>May 1, 2014</results_first_submitted>
  <results_first_submitted_qc>May 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2014</results_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>ER-negative</keyword>
  <keyword>Allred Score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogen Receptor Modulators</mesh_term>
    <mesh_term>Estrogen Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm</title>
          <description>AZ6244: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD6244</title>
          <description>AZ6244: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.75" lower_limit="56" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Increase of ER Protein Expression in ER-Negative/Low Breast Cancer</title>
        <description>To evaluate in a clinical neoadjuvant model whether MEK inhibitor AZD6244 can increase ER protein expression in ER-negative/low breast cancer, as measured by the &quot;ER response rate&quot; by both standard immunohistochemistry and Allred Score.</description>
        <time_frame>2 years</time_frame>
        <population>Only 1 subject had evaluable study data</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>AZ6244: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15</description>
          </group>
        </group_list>
        <measure>
          <title>Increase of ER Protein Expression in ER-Negative/Low Breast Cancer</title>
          <description>To evaluate in a clinical neoadjuvant model whether MEK inhibitor AZD6244 can increase ER protein expression in ER-negative/low breast cancer, as measured by the &quot;ER response rate&quot; by both standard immunohistochemistry and Allred Score.</description>
          <population>Only 1 subject had evaluable study data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in ER-regulated Gene Expression in E-negative/Low Breast Cancer</title>
        <description>To assess for changes in ER-regulated gene expression in ER-negative/low breast tumors following AZD6244 therapy through assessment of protein expression by immunhistochemistry in paraffin embedded tissues.</description>
        <time_frame>2 Years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of ER Promoter Methylation in ER-negative/Low Breast Cancer</title>
        <description>To determine the rate of ER promoter methylation in ER-negative/low breast cancer tumors that do not attain an ER response following AZD6244 therapy.</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In Vitro Tamoxifen Response in Tumors</title>
        <description>To assess for in vitro tamoxifen response in tumors following therapy with AZD6244.</description>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study results not evaluated due to low accrual.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>AZ6244: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only 4 patients were enrolled and of these 4 only 1 patient had evaluable study data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Judith Hurley MD</name_or_title>
      <organization>University of Miami Sylvester Comprehensive Cancer Center</organization>
      <phone>305-243-6462</phone>
      <email>JHurley@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

